Patents by Inventor HEMU WANG

HEMU WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hepatitis B treatment vaccine base on inactivated whole recombinant Hansenula polymorpha cells which expresses HBsAg and HBcAg
    Patent number: 11191829
    Abstract: Provided is a hepatitis B treatment vaccine based on an inactivated whole recombinant Hansenula polymorpha cell which expresses HBsAg and HBcAg. An HBsAgVLP and an HBcAgVLP expressed in the recombinant Hansenula polymorpha cell are used as antigens, the amino acid sequence of the HBsAg expressed by the recombinant Hansenula polymorpha contains a total of 19 CTL epitopes, the amino acid sequence of the HBcAg expressed by the recombinant Hansenula polymorpha contains a total of 19 CTL epitopes, and the inactivated whole recombinant Hansenula polymorpha cell is used as an adjuvant.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: December 7, 2021
    Inventor: Hemu Wang
  • HEPATITIS B TREATMENT VACCINE BASE ON INACTIVATED WHOLE RECOMBINANT HANSENULA POLYMORPHA CELLS WHICH EXPRESSES HBSAG AND HBCAG
    Publication number: 20200376115
    Abstract: Provided is a hepatitis B treatment vaccine based on an inactivated whole recombinant Hansenula polymorpha cell which expresses HBsAg and HBcAg. An HBsAgVLP and an HBcAgVLP expressed in the recombinant Hansenula polymorpha cell are used as antigens, the amino acid sequence of the HBsAg expressed by the recombinant Hansenula polymorpha contains a total of 19 CTL epitopes, the amino acid sequence of the HBcAg expressed by the recombinant Hansenula polymorpha contains a total of 19 CTL epitopes, and the inactivated whole recombinant Hansenula polymorpha cell is used as an adjuvant.
    Type: Application
    Filed: March 16, 2017
    Publication date: December 3, 2020
    Inventor: Hemu WANG
  • Recombinant Hansenula polymorpha-based high dosage hepatitis B vaccine
    Patent number: 10821174
    Abstract: Provided is a recombinant Hansenula polymorpha-based high dosage hepatitis B vaccine, an HBsAg pure stock solution yield of a recombinant Hansenula polymorpha fermentation broth used for producing the hepatitis B vaccine being 300 mg/L-400 mg/L.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: November 3, 2020
    Inventor: Hemu Wang
  • Hepatitis B treatment vaccine on the basis of inactivated, whole recombinant Hansenula polymorpha cells expressing HBsAg
    Patent number: 10653772
    Abstract: A hepatitis B treatment vaccine on the basis of inactivated, whole recombinant Hansenula polymorpha cells expressing HBsAg. The vaccine is the HBsAg expressed in recombinant Hansenula polymorpha cells. 108 cells contain 6-10 ?g HBsAg as an antigen; the vaccine contains a total of 16-21 HBsAg-specific CTL epitopes; the vaccine uses optimized inactivated, fully recombinant Hansenula polymorpha cells as an adjuvant.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: May 19, 2020
    Inventor: Hemu Wang
  • HEPATITIS B TREATMENT VACCINE ON THE BASIS OF INACTIVATED, WHOLE RECOMBINANT HANSENULA POLYMORPHA CELLS EXPRESSING HBSAG
    Publication number: 20190216921
    Abstract: A hepatitis B treatment vaccine on the basis of inactivated, fully recombinant Hansenula cells expressing HBsAg. The vaccine is the HBsAg expressed in recombinant Hansenula cells. 108 cells contain 6-10 ?g HBsAg as an antigen; the vaccine contains a total of 16-21 HBsAg-specific CTL epitopes; the vaccine uses optimized inactivated, fully recombinant Hansenula cells as an adjuvant.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 18, 2019
    Inventor: Hemu Wang
  • RECOMBINANT HANSENULA POLYMORPHA-BASED HIGH DOSAGE HEPATITIS B VACCINE
    Publication number: 20190083608
    Abstract: Provided is a recombinant Hansenula polymorpha-based high dosage hepatitis B vaccine, an HBsAg pure stock solution yield of a recombinant Hansenula polymorpha fermentation broth used for producing the hepatitis B vaccine being 300 mg/L-400 mg/L.
    Type: Application
    Filed: March 16, 2017
    Publication date: March 21, 2019
    Inventors: HEMU WANG, CHANGHUA WANG, JUN YANG